EGFR and neoplasm: The VOLFI trial demonstrated strong tumor shrinkage with triplet plus panitumumab for RAS wild-type mCRC6, so it would be worthwhile to further evaluate triplet plus cetuximab, which is a distinct anti-EGFR mAb from panitumumab in the aspect of administration method and clinical pharmacology7.